Page Arthur B lessened its stake in Johnson & Johnson (NYSE:JNJ) by 5.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,975 shares of the company’s stock after selling 1,555 shares during the quarter. Johnson & Johnson accounts for about 3.6% of Page Arthur B’s investment portfolio, making the stock its 7th biggest holding. Page Arthur B’s holdings in Johnson & Johnson were worth $4,075,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of JNJ. Geode Capital Management LLC lifted its stake in Johnson & Johnson by 1.5% in the 1st quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock valued at $5,100,421,000 after acquiring an additional 572,077 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Johnson & Johnson by 10.8% during the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after acquiring an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Johnson & Johnson by 7.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after purchasing an additional 2,118,870 shares during the last quarter. Capital World Investors lifted its position in shares of Johnson & Johnson by 182.9% in the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after purchasing an additional 13,703,905 shares in the last quarter. Finally, Morgan Stanley boosted its holdings in Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after purchasing an additional 54,563 shares during the last quarter. 68.44% of the stock is owned by institutional investors.
JNJ has been the topic of several analyst reports. SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. Barclays raised their price target on Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Morgan Stanley upped their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Finally, Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $140.00 to $155.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and an average target price of $163.38.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.58 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 7.85 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.77%. The ex-dividend date is Monday, August 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.